financetom
Business
financetom
/
Business
/
Nvidia's forecast dampens AI enthusiasm in other tech stocks
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nvidia's forecast dampens AI enthusiasm in other tech stocks
Aug 31, 2024 4:58 AM

(Reuters) -Shares of Nvidia ( NVDA ) and other technology heavyweights fell late on Wednesday, a discouraging sign for investors betting that a strong forecast from the dominant seller of AI chips would fuel fresh gains in Wall Street's most valuable companies.

Nasdaq futures fell about 1% following Nvidia's ( NVDA ) quarterly earnings report, suggesting traders expect tech stocks to lose ground on Thursday.

Nvidia ( NVDA ) dropped almost 7% and lost $200 billion in stock market value after it forecast third-quarter gross margins that could miss market estimates and revenue that was largely in line. A handful of other AI-related companies shed around $100 billion in combined value. 

Shares of Broadcom ( AVGO ) and Advanced Micro Devices ( AMD ) were each down about 2%. Microsoft ( MSFT ) and Amazon ( AMZN ) each dipped almost 1%.

If Wednesday's late-day dip in Nvidia ( NVDA ) shares extends into Thursday, it would be well short of the 11% price swing the options market had priced for the shares, according to data from options analytics firm ORATS.

Surging demand for its AI chips helped Nvidia ( NVDA ) crush consensus analyst estimates for several quarters, a trend that led investors to expect the company to exceed forecasts by higher and higher margins.

Nvidia's ( NVDA ) soft forecasts overshadowed a beat on second-quarter revenue and adjusted earnings as well as the unveiling of a $50 billion share buyback.

"They beat but this was just one of those situations where expectations were so high. I don't know that they could have had a good enough number for people to be happy," said JJ Kinahan, CEO of IG North America and president of online broker Tastytrade.    

The lackluster response to Nvidia's ( NVDA ) earnings report could help set the tone for market sentiment heading into what is historically a volatile time of the year. The S&P 500 has fallen in September by an average of 0.8% since World War Two, the worst performance of any month, according to CFRA data.

Investors are also watching next week's U.S. employment report for signs on whether the labor market weakness that roiled stocks in early August has dissipated.

Optimism about AI technology, in part due to Nvidia's ( NVDA ) explosive growth, has fueled gains on Wall Street over the past year.

However, confidence in that rally has wavered in recent weeks following an earnings season that saw investors punish shares of tech companies whose results failed to justify rich valuations.

Investors have also become concerned about increases in already hefty spending by Microsoft ( MSFT ), Alphabet and other major players in the race to dominate emerging AI technology. Microsoft ( MSFT ) and Alphabet's stocks remain down since their reports last month.

Nvidia ( NVDA ) forecast revenue of $32.5 billion, plus or minus 2%, for its fiscal third quarter, compared with analysts' average estimate of $31.8 billion, according to LSEG data. That revenue forecast implies 80% growth from the year-ago quarter.

The Santa Clara, California-based company expects adjusted gross margin of 75%, plus or minus 50 basis points, in the third quarter. Analysts on average forecast gross margin to be 75.5%, according to LSEG data. 

Nvidia's ( NVDA ) stock dropped 2.1% in Wednesday's session, ahead of its report. It remains up about 150% so far in 2024, making it the biggest winner in Wall Street's AI rally.

Nvidia's ( NVDA ) stock was valued at 36 times earnings ahead of its quarterly report, inexpensive compared to its average of 41 over the past five years. The S&P 500 is trading at 21 times expected earnings, compared to a five-year average of 18.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
--FDIC Acting Chair Says Agency to Ease Banks' Living-Will Mandates, Bloomberg Reports
--FDIC Acting Chair Says Agency to Ease Banks' Living-Will Mandates, Bloomberg Reports
Apr 8, 2025
10:45 AM EDT, 04/08/2025 (MT Newswires) -- Price: 61.92, Change: +3.07, Percent Change: +5.22 ...
Rio Tinto hopes Trump provides favorable path for Resolution copper mine
Rio Tinto hopes Trump provides favorable path for Resolution copper mine
Apr 8, 2025
SANTIAGO, April 8 (Reuters) - Miner Rio Tinto sees U.S. President Donald Trump's administration showing more interest in a bigger copper supply chain and hopes that will help push forward its Resolution mine project in Arizona, Rio's copper CEO Katie Jackson said on Tuesday. We hope that will be part of getting projects like Resolution to move, she told the...
Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps
Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps
Apr 8, 2025
Pacira BioSciences, Inc ( PCRX ). on Monday settled its litigations with Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and eVenus Pharmaceuticals Laboratories, Inc. related to patents for Exparel (bupivacaine liposome injectable suspension). Exparel is Pacira BioSciences' ( PCRX ) non-opioid analgesic pain management and is indicated for postsurgical analgesia. As part of the settlement, the parties will file...
Copyright 2023-2026 - www.financetom.com All Rights Reserved